Hebei Changshan Biochem Pharma (300255) — Capital Reinvestment Ratio

Latest as of June 2025: 0.27x

Hebei Changshan Biochem Pharma (300255) has a Capital Reinvestment Ratio of 0.27x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥70.22 Million) in capital expenditures (CN¥18.63 Million). Check tangible equity quality of Hebei Changshan Biochem Pharma to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.27x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥70.22 Million
CNY

Capital Expenditures

CN¥18.63 Million
CNY

Data as of

Jun 2025
Most recent filing

Hebei Changshan Biochem Pharma Capital Reinvestment Ratio (2009–2024)

This chart tracks Hebei Changshan Biochem Pharma's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Hebei Changshan Biochem Pharma cash conversion from operations.

Annual Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma (2009–2024)

Year-by-year Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma from 2009 to 2024. See Hebei Changshan Biochem Pharma free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 4.26x CN¥56.22 Million CN¥239.59 Million ▼ -39.9%
2023 7.10x CN¥33.73 Million CN¥239.32 Million ▼ -94.9%
2022 137.97x CN¥3.13 Million CN¥431.22 Million ▲ +28.6%
2021 107.29x CN¥2.87 Million CN¥308.08 Million ▲ +13277.0%
2018 0.80x CN¥292.81 Million CN¥234.85 Million ▼ -17.8%
2017 0.98x CN¥162.28 Million CN¥158.30 Million ▲ +73.8%
2016 0.56x CN¥171.96 Million CN¥96.52 Million ▼ -68.6%
2011 1.79x CN¥17.04 Million CN¥30.43 Million ▲ +39.0%
2010 1.28x CN¥29.25 Million CN¥37.56 Million ▲ +29.3%
2009 0.99x CN¥24.21 Million CN¥24.05 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow